ClinicalTrials.gg

Program

Metronidazole

Also written as “metronidazole 1% gel”, “Metronidazole Tablet” and “metronidazole”.

Its studies are mostly in Intraabdominal Infections · Vaginosis, Bacterial · Rosacea · Appendicitis · Skin Manifestations, led by 11 companies.

Furthest: phase 4, since Sep 12, 200527 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer80 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Galderma Group40 open or runningphase 4since Feb 16, 2007Feb 16, 2007none ahead
S.L.A. Pharma40 open or runningphase 3since Jul 30, 2007Jul 30, 2007none ahead
Curatek Pharmaceuticals20 open or runningphase 3since Dec 1, 2014Dec 1, 2014none ahead
Par Health20 open or runningphase 1since Jun 16, 2011Jun 16, 2011none ahead
Teva Pharmaceutical Industries20 open or runningphase 2since Nov 24, 2009Nov 24, 2009none ahead
appili-therapeutics-inc10 open or runningphase 1since Nov 6, 2017Nov 6, 2017none ahead
biorasi-llc10 open or runningphase 3since Mar 12, 2015Mar 12, 2015none ahead
Dr. Reddy's Laboratories10 open or runningphase 2since Mar 19, 2012Mar 19, 2012none ahead
Insud Pharma10 open or runningphase 4since Mar 4, 2015Mar 4, 2015none ahead
Saptalis Pharmaceuticals11 open or runningphase 2since Aug 8, 2025Aug 8, 2025none ahead

Also a collaborator on its studies: allergan-sales-llc, AbbVie, algorithme-pharma-inc and pricara-unit-of-ortho-mcneil-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Sep 12, 2005.

  1. Jul 20, 2011Phase 1 study in InfectionsPfizer · NCT01407016 · 6 enrolled · Japan
  2. Aug 26, 2011Phase 4 study in RosaceaGalderma Group · NCT01426269 · 235 enrolled · United States
  3. Oct 11, 2011Phase 3 study in Intraabdominal InfectionsPfizer · NCT01473836 · 38 enrolled · Japan
  4. Dec 19, 2011Phase 3 study in Complicated Intra-Abdominal InfectionPfizer · NCT01499290 · 493 enrolled · United States, Argentina, Bulgaria and more
  5. Feb 9, 2012Phase 1 study in HealthyPfizer · NCT01534247 · 28 enrolled · United States
  6. Mar 19, 2012Dr. Reddy's Laboratories's first study: phase 2 study in Clostridium Difficile Associated DiarrheaNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01559545 · 60 enrolled · India
  7. Nov 5, 2012Phase 3 study in Complicated Intra-abdominal InfectionPfizer · NCT01726023 · 486 enrolled · China, Korea, Republic of, Vietnam
  8. Dec 1, 2014Curatek Pharmaceuticals's first studies: 2 phase 3 studies in VaginitisNew to Curatek PharmaceuticalsCuratek Pharmaceuticals · NCT02308033, NCT02308007
  9. Mar 4, 2015Insud Pharma's first study: phase 4 study in Vaginosis, BacterialNew to Insud PharmaInsud Pharma · NCT02392026 · 60 enrolled · United States
  10. Mar 12, 2015biorasi-llc's first study: phase 3 study in RosaceaNew to biorasi-llcbiorasi-llc · NCT02393937 · 963 enrolled · United States
  11. May 25, 2015Phase 2 study in Complicated Intra-abdominal InfectionsPfizer · NCT02475733 · 83 enrolled · United States, Czechia, Greece and more
  12. Nov 6, 2017appili-therapeutics-inc's first study: phase 1 study in BioequivalenceNew to appili-therapeutics-incappili-therapeutics-inc · NCT03337126 · 48 enrolled · Canada
  13. Jan 15, 2020Phase 2 study in Pilonidal SinusS.L.A. Pharma · NCT04273997 · 80 enrolled · Turkey
  14. Aug 8, 2025Saptalis Pharmaceuticals's first study: phase 2 study in Bacterial InfectionsNew to Saptalis PharmaceuticalsSaptalis Pharmaceuticals · NCT07146217 · 30 planned · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07146217Bacterial Infections · United States2Not yet recruitingSaptalis PharmaceuticalsJul 202630
NCT04273997Pilonidal Sinus · Turkey2UNKNOWNS.L.A. PharmaFeb 1, 202280
NCT03337126Bioequivalence · Canada1Completedappili-therapeutics-incDec 13, 201748
NCT02475733Complicated Intra-abdominal Infections · United States, Czechia, Greece and more2CompletedPfizerJun 1, 201783
NCT02393937Rosacea · United States3Completedbiorasi-llcJul 2015963
NCT02392026Vaginosis, Bacterial · United States4CompletedInsud PharmaOct 5, 201660
NCT02308033Vaginitis · United States3CompletedCuratek PharmaceuticalsJun 2017204
NCT02308007Vaginitis · United States3CompletedCuratek PharmaceuticalsJun 2018475
NCT01726023Complicated Intra-abdominal Infection · China, Korea, Republic of, Vietnam3CompletedPfizerMar 2015486
NCT01559545Clostridium Difficile Associated Diarrhea · India2CompletedDr. Reddy's LaboratoriesFeb 201360
NCT01534247Healthy · United States1CompletedPfizerJul 201228
NCT01499290Complicated Intra-Abdominal Infection · United States, Argentina, Bulgaria and more3CompletedPfizerApr 2014493
NCT01473836Intraabdominal Infections · Japan3CompletedPfizerOct 201238
NCT01426269Rosacea · United States4CompletedGalderma GroupJun 2013235
NCT01407016Infections · Japan1CompletedPfizerSep 20116
NCT01380522Lecithin Cholesterol Acyltransferase Deficiency · Canada1CompletedPar HealthSep 200218
NCT01380509Fasting · Canada1CompletedPar HealthSep 200228
NCT01139047Skin Manifestations · United States4CompletedGalderma GroupJun 201077
NCT01139008Skin Manifestations · United States4CompletedGalderma GroupJun 201080
NCT01020877Healthy · United States1CompletedTeva Pharmaceutical IndustriesNov 200138
NCT01020396Vaginosis, Bacterial · United States2CompletedTeva Pharmaceutical IndustriesMar 2003579
NCT00774969Perianal Crohns' · United Kingdom1CompletedS.L.A. PharmaApr 200819
NCT00774722Haemorrhoidectomy · United Kingdom3CompletedS.L.A. PharmaMar 200859
NCT00509639Crohn Disease · United States, United Kingdom3CompletedS.L.A. PharmaFeb 200874
NCT00436527Rosacea · United States4CompletedGalderma GroupAug 200626
NCT00230971Appendicitis · Australia, China, Denmark and more4CompletedPfizerSep 2008473
NCT00195351Appendicitis · United States, Argentina, Brazil and more4CompletedPfizerFeb 2008467

How it is read

Names in the registry

  • “Metronidazole”, 20 entries
  • “metronidazole 1% gel”, 2 entries
  • “Metronidazole Tablet”, 2 entries
  • “metronidazole”, 2 entries
  • “Likmez® (metronidazole) Oral Suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.